4D Molecular Therapeutics, Inc. (FDMT) Investor Relations Documents

4D Molecular Therapeutics, Inc. (FDMT) investor relations documents from the company's IR site: 3 presentations, 37 press releases; latest deck 2026-08-21. Read in-app with summaries. First-party data.

4DMT Corporate Presentation – August 2026: 4D Molecular Therapeutics presents its pipeline, highlighting 4D-150 for retinal diseases and 4D-710 for Cystic Fibrosis, with a focus on transformative therapies.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-21Presentation4DMT Corporate Presentation – August 2026
2026-08-14Press releasePress release
2026-08-14Press release4DMT Announces New Employment Inducement Grants
2026-08-13Press releasePress release
2026-08-13Press release4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
2026-07-18Press releasePress release
2026-07-18Press release4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
2026-07-17Presentation4DMT Corporate Presentation – July 2026
2026-07-17Press releasePress release
2026-07-17Press release4DMT Announces New Employment Inducement Grants
2026-06-30Press releasePress release
2026-06-30Press release4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
2026-06-29Press releasePress release
2026-06-29Press releasePress release
2026-06-29Press release4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
2026-06-29Press release4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
2026-06-12Press releasePress release
2026-06-12Press release4DMT Announces New Employment Inducement Grants
2026-05-27Press release4DMT to Participate in Upcoming Investor Conferences
2026-05-15Press releasePress release
2026-05-15Press release4DMT Announces New Employment Inducement Grants
2026-05-07Press releasePress release
2026-05-07Press release4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
2026-05-04Press releasePress release
2026-05-04Press release4DMT to Participate in Upcoming Investor Conferences
2026-04-17Press releasePress release
2026-04-17Press release4DMT Announces New Employment Inducement Grants
2026-03-18Press releasePress release
2026-03-18Press release4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
2026-03-16Press release4DMT to Participate in Upcoming Investor Meetings
2026-02-19Press release4DMT to Participate in Upcoming Investor Conferences
2026-02-13Press releasePress release
2026-02-13Press release4DMT Announces New Employment Inducement Grants
2026-02-09Press releasePress release
2026-02-09Press release4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
2026-01-16Press releasePress release
2026-01-16Press release4DMT Announces New Employment Inducement Grants
2026-01-14PresentationJ.P. Morgan 2026 Presentation
2026-01-07Press releasePress release
2026-01-07Press release4DMT Provides Company Update and Anticipated Development Milestones for 2026

FDMT overview · FDMT earnings · FDMT financials · FDMT KPIs · FDMT ownership · FDMT peers · FDMT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.